Susceptibility of human endogenous retrovirus type K to reverse transcriptase inhibitors

Rafael Contreras-Galindo, Derek Dube, Koh Fujinag, Mark H. Kaplan, David M. Markovitz

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


Human endogenous retroviruses (HERVs) make up 8% of the human genome. The HERV type K (HERV-K) HML-2 (HK2) family contains proviruses that are the most recent entrants into the human germ line and are transcriptionally active. In HIV-1 infection and cancer, HK2 genes produce retroviral particles that appear to be infectious, yet the replication capacity of these viruses and potential pathogenicity has been difficult to ascertain. In this report, we screened the efficacy of commercially available reverse transcriptase inhibitors (RTIs) at inhibiting the enzymatic activity of HK2 RT and HK2 genomic replication. Interestingly, only one provirus, K103, was found to encode a functional RT among those examined. Several nucleoside analogue RTIs (NRTIs) blocked K103 RT activity and consistently inhibited the replication of HK2 genomes. The NRTIs zidovudine (AZT), stavudine (d4T), didanosine (ddI), and lamivudine (3TC), and the nucleotide RTI inhibitor tenofovir (TDF), show efficacy in blocking K103 RT. HIV-1-specific nonnucleoside RTIs (NNRTIs), protease inhibitors (PIs), and integrase inhibitors (IIs) did not affect HK2, except for the NNRTI etravirine (ETV). The inhibition of HK2 infectivity by NRTIs appears to take place at either the reverse transcription step of the viral genome prior to HK2 viral particle formation and/or in the infected cells. Inhibition of HK2 by these drugs will be useful in suppressing HK2 infectivity if these viruses prove to be pathogenic in cancer, neurological disorders, or other diseases associated with HK2. The present studies also elucidate a key aspect of the life cycle of HK2, specifically addressing how they do, and/or did, replicate.

Original languageEnglish (US)
Article numbere01309-17
JournalJournal of virology
Issue number23
StatePublished - Dec 1 2017
Externally publishedYes

Bibliographical note

Funding Information:
This work was supported by grant K22 CA177824 from the National Cancer Institute and Research Supplement to Promote Diversity in Health-Related Research grant 3R01CA144043-03S1 from the National Institutes of Health to R.C.-G., a grant (05-5089) to M.H.K. from the Concerned Parents for AIDS Research (CPFA), and by grants RO1 AI062248 and RO1 CA144043 to D.M.M. from the National Institutes of Health. D.D. was supported by an NIH Ruth L. Kirschstein NRSA Individual Postdoctoral Fellowship (1 F32 AI106189-01).

Publisher Copyright:
© 2017 American Society for Microbiology.


  • AZT
  • HERV-K
  • NNRTIs
  • NRTIs
  • NtRTIs
  • Reverse transcriptase inhibitors


Dive into the research topics of 'Susceptibility of human endogenous retrovirus type K to reverse transcriptase inhibitors'. Together they form a unique fingerprint.

Cite this